DXCM · Dexcom Inc
$89.75
-1.73 (-1.89%)
At close · Aug 14
Market Cap
$33.87B
Shares
377.36M
Dexcom Inc Earnings Call Transcripts
Every quarterly earnings call for Dexcom Inc (DXCM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲18.4%
$769.60M
$101.20M
'22 Q3
22-10-27
▲16.8%
$815.20M
$91.80M
'22 Q4
23-02-09
▲17.9%
$741.50M
$48.60M
'23 Q1
23-04-27
▲25.2%
$871.30M
$115.90M
'23 Q2
23-07-27
▲26.7%
$975.00M
$120.70M
'23 Q3
23-10-26
▲26.9%
$1.03B
$256.30M
'23 Q4
24-02-08
▲24.2%
$921.00M
$146.40M
'24 Q1
24-04-25
▲15.3%
$1.00B
$143.50M
'24 Q2
24-07-25
▲2%
$994.20M
$134.60M
'24 Q3
24-10-24
▲7.6%
$1.11B
$151.70M
'24 Q4
25-02-13
▲12.5%
$1.04B
$105.40M
'25 Q1
25-05-01
▲15.2%
$1.16B
$179.80M
'25 Q2
25-07-30
▲21.6%
$1.21B
$283.80M
'25 Q3
25-10-30
▲13.1%
$1.26B
$267.30M
'25 Q4
26-02-12
▲15%
$1.19B
$199.50M
'26 Q1
26-04-30
LATEST
▲13.1%
$1.31B
$249.10M
'26 Q2
26-07-30
Earnings call
FY26 · Q2
2026-07-30
DexCom, Inc. Second Quarter 2026 Earnings Release Conference Call
Confident tone
Type 2 non-insulin expansion and coverage
CONNECT clinical trial results
Product launches and app platform
Revenue
$1.31B
▲ 13.1% YoY Diluted EPS
$0.64
▲ 42.2% YoY Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Dexcom Inc Q1 FY2026 Earnings Call
Revenue
$1.19B
▲ 15% YoY Diluted EPS
$0.51
▲ 88.9% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Dexcom Inc Q4 FY2025 Earnings Call
Confident tone
Stelo and over-the-counter growth
Reimbursement and covered lives
Customer experience and software innovation
Revenue
$1.26B*
▲ 13.1% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Dexcom Inc Q3 FY2025 Earnings Call
Confident tone
Type 2 non-insulin access and coverage
DexCom Smart Basal
Gross margin and 10-day to 15-day transition
Revenue
$1.21B
▲ 21.6% YoY Diluted EPS
$0.70
▲ 105.9% YoY Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Dexcom Inc Q2 FY2025 Earnings Call
Confident tone
Type 2 non-insulin reimbursement expansion
Stelo over-the-counter biosensor
DME channel recovery
Revenue
$1.16B
▲ 15.2% YoY Diluted EPS
$0.45
▲ 28.6% YoY Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Dexcom Inc Q1 FY2025 Earnings Call
Confident tone
Type 2 non-insulin coverage expansion
Stelo over-the-counter CGM
FDA warning letter
Revenue
$1.04B
▲ 12.5% YoY Diluted EPS
$0.27
▼ 25% YoY Gross margin
56.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Dexcom Inc Q4 FY2024 Earnings Call
Confident tone
Stella over-the-counter launch
International growth and reimbursement
AI and platform partnerships
Revenue
$1.11B*
▲ 7.6% YoY Gross margin
58.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-24
Dexcom Inc Q3 FY2024 Earnings Call
Positive tone
Stelo launch and over-the-counter biosensor
Reimbursement and market access expansion
International growth and G7 / DexCom ONE+ expansion
Revenue
$994.20M
▲ 2% YoY Diluted EPS
$0.34
▲ 17.2% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-25
Dexcom Inc Q2 FY2024 Earnings Call
Cautious tone
Revenue per customer and rebate dynamics
DME channel underperformance
International softness
Revenue
$1.00B
▲ 15.3% YoY Diluted EPS
$0.35
▲ 25% YoY Gross margin
62.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Dexcom Inc Q1 FY2024 Earnings Call
Confident tone
Stelo over-the-counter launch
Type 2 basal and hypoglycemia unawareness adoption
U.S. commercial coverage expansion
Revenue
$921.00M
▲ 24.2% YoY Diluted EPS
$0.36
▲ 200% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-08
Dexcom Inc Q4 FY2023 Earnings Call
Confident tone
Stelo product launch for type 2 non-insulin
Margin and profitability trajectory
G7 product rollout and reception
Revenue
$1.03B*
▲ 26.9% YoY Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Dexcom Inc Q3 FY2023 Earnings Call
Revenue
$975.00M
▲ 26.7% YoY Diluted EPS
$0.29
▲ 20.8% YoY Gross margin
63.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Dexcom Inc Q2 FY2023 Earnings Call
Revenue
$871.30M
▲ 25.2% YoY Diluted EPS
$0.28
▲ 133.3% YoY Gross margin
62.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Dexcom Inc Q1 FY2023 Earnings Call
Revenue
$741.50M
▲ 17.9% YoY Diluted EPS
$0.12
▼ 47.8% YoY Gross margin
62.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-09
Dexcom Inc Q4 FY2022 Earnings Call
Revenue
$815.20M*
▲ 16.8% YoY Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Dexcom Inc Q3 FY2022 Earnings Call
Revenue
$769.60M
▲ 18.4% YoY Diluted EPS
$0.24
▲ 14.3% YoY Gross margin
64.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Dexcom Inc Q2 FY2022 Earnings Call
Revenue
$696.20M
▲ 17% YoY Diluted EPS
$0.12
▼ 36.8% YoY Gross margin
64.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Dexcom Inc Q1 FY2022 Earnings Call
Revenue
$628.80M
▲ 24.5% YoY Diluted EPS
$0.23
▲ 64.3% YoY Gross margin
63.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-10
Dexcom Inc Q4 FY2021 Earnings Call
Revenue
$698.20M*
▲ 22.7% YoY Gross margin
67.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Dexcom Inc Q3 FY2021 Earnings Call
Revenue
$650.20M
▲ 29.8% YoY Diluted EPS
$0.21
▲ 15.1% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Dexcom Inc Q2 FY2021 Earnings Call
Revenue
$595.10M
▲ 31.7% YoY Diluted EPS
$0.19
▲ 58.3% YoY Gross margin
70.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Dexcom Inc Q1 FY2021 Earnings Call
Revenue
$505.00M
▲ 24.7% YoY Diluted EPS
$0.14
▲ 166.7% YoY Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Dexcom Inc Q4 FY2020 Earnings Call
Revenue
$568.90M*
▲ 22.9% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-27
Dexcom Inc Q3 FY2020 Earnings Call
Revenue
$500.90M
▲ 26.4% YoY Diluted EPS
$0.18
▲ 46% YoY Gross margin
68.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-28
Dexcom Inc Q2 FY2020 Earnings Call
Revenue
$451.80M
▲ 34.3% YoY Diluted EPS
$0.12
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-28
Dexcom Inc Q1 FY2020 Earnings Call
Revenue
$405.10M
▲ 44.4% YoY Diluted EPS
$0.05
Gross margin
63.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Dexcom Inc Q4 FY2019 Earnings Call
Revenue
$462.80M
▲ 36.9% YoY Diluted EPS
$0.25
Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1093557
CUSIP
252131107
13F (30d)
885 filings
854 filers
Visit website
Investor relations